JP2021531299A - 慢性咳嗽、息切れ、及び呼吸困難の治療 - Google Patents

慢性咳嗽、息切れ、及び呼吸困難の治療 Download PDF

Info

Publication number
JP2021531299A
JP2021531299A JP2021503736A JP2021503736A JP2021531299A JP 2021531299 A JP2021531299 A JP 2021531299A JP 2021503736 A JP2021503736 A JP 2021503736A JP 2021503736 A JP2021503736 A JP 2021503736A JP 2021531299 A JP2021531299 A JP 2021531299A
Authority
JP
Japan
Prior art keywords
cough
treatment
nalbuphine
dyspnea
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021503736A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531299A5 (https=
Inventor
トーマス シャーシャ，
Original Assignee
トレビ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トレビ セラピューティクス インコーポレイテッド filed Critical トレビ セラピューティクス インコーポレイテッド
Publication of JP2021531299A publication Critical patent/JP2021531299A/ja
Publication of JP2021531299A5 publication Critical patent/JP2021531299A5/ja
Priority to JP2024124443A priority Critical patent/JP2024153828A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021503736A 2018-07-23 2019-07-23 慢性咳嗽、息切れ、及び呼吸困難の治療 Pending JP2021531299A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024124443A JP2024153828A (ja) 2018-07-23 2024-07-31 慢性咳嗽、息切れ、及び呼吸困難の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862701902P 2018-07-23 2018-07-23
US62/701,902 2018-07-23
PCT/US2019/042994 WO2020023486A1 (en) 2018-07-23 2019-07-23 Treatment of chronic cough, breathlessness and dyspnea

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024124443A Division JP2024153828A (ja) 2018-07-23 2024-07-31 慢性咳嗽、息切れ、及び呼吸困難の治療

Publications (2)

Publication Number Publication Date
JP2021531299A true JP2021531299A (ja) 2021-11-18
JP2021531299A5 JP2021531299A5 (https=) 2022-07-29

Family

ID=69162461

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021503736A Pending JP2021531299A (ja) 2018-07-23 2019-07-23 慢性咳嗽、息切れ、及び呼吸困難の治療
JP2024124443A Pending JP2024153828A (ja) 2018-07-23 2024-07-31 慢性咳嗽、息切れ、及び呼吸困難の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024124443A Pending JP2024153828A (ja) 2018-07-23 2024-07-31 慢性咳嗽、息切れ、及び呼吸困難の治療

Country Status (12)

Country Link
US (5) US20200022974A1 (https=)
EP (1) EP3826635A4 (https=)
JP (2) JP2021531299A (https=)
KR (1) KR20210035854A (https=)
CN (5) CN112703000B (https=)
AU (2) AU2019309913B2 (https=)
BR (2) BR122023024228A2 (https=)
CA (1) CA3106995A1 (https=)
IL (2) IL318587A (https=)
MX (2) MX2021000908A (https=)
SG (1) SG11202100580UA (https=)
WO (1) WO2020023486A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL318587A (en) 2018-07-23 2025-03-01 Trevi Therapeutics Inc Treatment of chronic cough, shortness of breath and wheezing
IL294601A (en) 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine
WO2026025110A1 (en) * 2024-07-26 2026-01-29 Trevi Therapeutics, Inc. Treatment of refractory chronic cough

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080207667A1 (en) * 2007-02-23 2008-08-28 Rhame Robert W Use of nalbuphine and related compounds to treat symptoms of respiratory problems
JP2014518252A (ja) * 2011-07-05 2014-07-28 バイオコピア リミテッド 薬剤の組合せ、および咳嗽状態の治療における使用
JP2016506398A (ja) * 2012-12-14 2016-03-03 トレビ セラピューティクス インコーポレイテッド そう痒の処置法
WO2017118584A1 (en) * 2016-01-08 2017-07-13 Nerre Therapeutics Limited Orvepitant for the treatment of chronic cough
WO2018013788A1 (en) * 2016-07-14 2018-01-18 Children's Hospital Medical Center Methods for treating fibrosis

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443442A (en) 1979-12-21 1984-04-17 Skillern Scott D Method and composition for treatment of acne vulgaris
AU8952282A (en) 1982-08-25 1984-03-29 Joel E. Bernstein Method of treating pruritis and composition therefor
US4720384A (en) 1985-05-03 1988-01-19 E. I. Du Pont De Nemours And Company Manufacture of hollow fine tubular drug delivery systems
US20010006967A1 (en) 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
US6239154B1 (en) 1996-03-08 2001-05-29 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
DE69732868T2 (de) 1996-11-25 2006-04-13 Toray Industries, Inc. Mittel gegen Juckreiz
US6787149B1 (en) 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
US5760023A (en) 1997-07-14 1998-06-02 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
CA2288828A1 (en) 1997-07-14 1999-01-28 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
CN100340575C (zh) 1999-06-25 2007-10-03 杰南技术公司 人源化抗ErbB2抗体及其在制备药物中的应用
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
JP2001163784A (ja) 1999-12-06 2001-06-19 Toray Ind Inc 角膜または結膜用止痒剤
DE19960154A1 (de) * 1999-12-14 2001-07-12 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur transmucosalen Verabreichung von Oxycodon oder einem vergleichbaren Wirkstoff in der Mundhöhle, für die Anwendung in der Schmerztherapie und Suchttherapie
JP4370683B2 (ja) 2000-05-08 2009-11-25 東レ株式会社 そう痒疾患の検査方法
DE10116978A1 (de) 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
ITMI20010907A1 (it) 2001-05-02 2002-11-02 Valpharma Sa Impiego di antagonisti oppioidi per la prevenzione ed il controllo degli effetti collaterali prodotti dagli oppioidi
US20030054030A1 (en) 2001-09-13 2003-03-20 Gary Gordon Method and compositions for the treatment of pruritus
ES2654819T3 (es) 2001-10-18 2018-02-15 Nektar Therapeutics Conjugados poliméricos de antagonistas de opioides
US6703398B2 (en) 2001-11-26 2004-03-09 Oliver Yoa-Pu Hu Orally administered analgesic compositions containing nalbuphine
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1492505B1 (en) 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
DE10229842A1 (de) 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
WO2004008099A2 (en) 2002-07-15 2004-01-22 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
SI2263691T1 (sl) 2002-07-15 2012-12-31 F. Hoffmann-La Roche Ag Zdravljenje raka z rekombinantnim humaniziranim monoklonskim anti-ErbB2 protitelesom 2C4 (rhuMAb 2C4)
US7381721B2 (en) 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
CA2811272C (en) 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
US7459146B2 (en) 2003-05-30 2008-12-02 3M Innovative Properties Company Stabilized aerosol dispersions
MXPA06003392A (es) 2003-09-25 2006-06-08 Euro Celtique Sa Combinacion farmaceutica de hidrocodona y naltrexona.
TW200533355A (en) 2004-03-30 2005-10-16 Toray Industries Antipruritic agent
AU2005249581A1 (en) 2004-06-03 2005-12-15 Jonathan J. Burbaum Pharmaceutical compositions for the treatment of pruritus
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
PL1888033T3 (pl) 2005-06-09 2014-09-30 Meda Ab Sposób i kompozycja do leczenia chorób zapalnych
US8394812B2 (en) * 2005-08-24 2013-03-12 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
EP1931315B1 (en) 2005-08-24 2013-10-16 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
EP1942903A4 (en) 2005-08-30 2011-01-12 Univ Kingston POTENTIATING THE THERAPEUTIC EFFECT OF AN OPIOID RECEPTOR AGONIST AND / OR INHIBITING OR REVERSING THE TOLERANCE FOR OPIOID RECEPTOR AGONISTS WITH A ULTRANOUS DOSE OF AN ALPHA-2 RECEPTOR ANTAGONIST
EP2749571A3 (en) 2006-01-10 2014-08-13 ZymoGenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using IL-31RA and OSMRb antagonists
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
JP2008109898A (ja) 2006-10-31 2008-05-15 Toray Ind Inc 鎮痒作用を有する化合物のスクリーニング方法
RU2500685C2 (ru) 2006-11-10 2013-12-10 Кара Терапеутикс, Инк Синтетические пептидные амиды
EP2101774A2 (en) 2006-11-22 2009-09-23 Progenics Pharmaceuticals, Inc. 7,8-saturated-4,5-epoxy-morphinanium analogs
BRPI0719327A2 (pt) 2006-11-22 2014-02-04 Progenics Pharm Inc N-óxidos de análogos de 4,5-epóxi-morfinano
JP2010510325A (ja) 2006-11-22 2010-04-02 プロジェニックス ファーマスーティカルス インコーポレーテッド ７，８−飽和−４，５−エポキシ−モルフィナニウム類似体の（ｓ）−ｎ−立体異性体
PL2137191T3 (pl) 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
CA2682608A1 (en) 2007-03-30 2008-10-09 Tioga Pharmaceuticals, Inc. Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome
CL2008001112A1 (es) 2007-04-20 2008-12-19 Novartis Ag Usos de compuestos derivados de pirido[2,3-d]pirimidin-4-ona para tratar comezon o un trastorno relacionado con comezon; combinacion de los compuestos con otro farmaco; y uso de la combinacion para tratar la comezon o un trastorno relacionado con comezon.
ES2396600T3 (es) 2007-04-23 2013-02-22 Symrise Ag Ésteres de polietilenglicol y preparaciones cosméticas y/o dermatológicas
BRPI0813230A2 (pt) 2007-06-28 2014-12-23 Novartis Ag Moduladores de calicreína 7
AU2008296905A1 (en) 2007-09-04 2009-03-12 Alpharma Pharmaceuticals, Llc A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
WO2009047562A1 (en) 2007-10-08 2009-04-16 Serentis Limited Methods and compositions for the treatment of pruritus
WO2009070733A1 (en) 2007-11-26 2009-06-04 Pharmacofore, Inc. Peripheral phenolic opioid antagonist
ES2671897T3 (es) 2008-02-14 2018-06-11 Alkermes, Inc. Compuestos opioides selectivos
US8686040B2 (en) 2008-03-31 2014-04-01 Rdd Pharma Ltd. Method for treating anal pruritis and other perianal disorders
WO2009132313A2 (en) 2008-04-25 2009-10-29 Progenics Pharmaceuticals, Inc. Morphinan derivatives of organic and inorganic acids
CA2740440A1 (en) * 2008-10-14 2010-04-22 Dyax Corp. Use of igf-ii/igf-iie binding proteins for the treatment and prevention of systemic sclerosis-associated pulmonary fibrosis
US20120077803A1 (en) 2009-02-24 2012-03-29 Novartis Ag Uses Of NK Receptor Antagonists
US20100227876A1 (en) 2009-03-06 2010-09-09 Rechfensen Llp Methods of Reducing Side Effects of Analgesics
EP2408303A4 (en) 2009-03-19 2012-07-25 Alkermes Inc MORPHINANE DERIVATIVES HAVING HIGH ORAL BIOLOGICAL AVAILABILITY
EP2421515A2 (de) 2009-04-22 2012-02-29 Lars Holger Hermann Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid- antagonisten
CA2709800C (en) * 2009-07-15 2023-01-10 Universite Laval Method and device for administering oxygen to a patient and monitoring the patient
PH12012501552A1 (en) 2010-01-29 2017-04-26 Toray Industries Therapeutic or prophylactic agent for biliary diseases
IT1398930B1 (it) 2010-03-24 2013-03-28 Molteni & C Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi.
FR2963889B1 (fr) * 2010-08-20 2013-04-12 Debregeas Et Associes Pharma Formulations a base de nalbuphine et leurs utilisations
JP2012087101A (ja) 2010-10-21 2012-05-10 Holger Hermann Lars オピオイドおよびオピオイド拮抗薬を含む微粒子医薬組成物
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
AU2014308606B2 (en) * 2013-08-23 2017-08-03 Afferent Pharmaceuticals Inc. Diaminopyrimidine P2X3 and P2X 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough
WO2015192071A1 (en) 2014-06-13 2015-12-17 Trevi Therapeutics, Inc. Methods for treating pruritus
TW201735914A (zh) * 2015-12-22 2017-10-16 阿斯特捷利康公司 用於治療慢性阻塞性肺疾病之醫藥組成物
EP3393463B1 (en) * 2015-12-23 2021-01-20 Conrig Pharma ApS Suplatast tosilate for treating cough associated with interstitial lung disease
US20170216277A1 (en) 2016-01-06 2017-08-03 Trevi Therapeutics, Inc. Therapeutic use of nalbuphine without aquaretic effects
CN105560202B (zh) 2016-03-11 2019-05-24 广州玻思韬控释药业有限公司 一种盐酸纳布啡凝胶骨架缓释片的制备方法及应用
CN109310656A (zh) 2016-03-21 2019-02-05 特雷维治疗股份有限公司 尿毒症性瘙痒症的治疗
WO2018044942A1 (en) * 2016-08-31 2018-03-08 Patara Pharma, LLC Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
MX2019004804A (es) 2016-10-25 2019-08-22 Trevi Therapeutics Inc Tratamiento para el prurigo nodula.
CN112672743A (zh) 2018-07-11 2021-04-16 特雷维治疗股份有限公司 肝病瘙痒症状的治疗
IL318587A (en) 2018-07-23 2025-03-01 Trevi Therapeutics Inc Treatment of chronic cough, shortness of breath and wheezing

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080207667A1 (en) * 2007-02-23 2008-08-28 Rhame Robert W Use of nalbuphine and related compounds to treat symptoms of respiratory problems
JP2014518252A (ja) * 2011-07-05 2014-07-28 バイオコピア リミテッド 薬剤の組合せ、および咳嗽状態の治療における使用
JP2016506398A (ja) * 2012-12-14 2016-03-03 トレビ セラピューティクス インコーポレイテッド そう痒の処置法
WO2017118584A1 (en) * 2016-01-08 2017-07-13 Nerre Therapeutics Limited Orvepitant for the treatment of chronic cough
WO2018013788A1 (en) * 2016-07-14 2018-01-18 Children's Hospital Medical Center Methods for treating fibrosis

Also Published As

Publication number Publication date
IL318587A (en) 2025-03-01
CN112703000A (zh) 2021-04-23
AU2019309913A1 (en) 2021-03-11
SG11202100580UA (en) 2021-02-25
JP2024153828A (ja) 2024-10-29
EP3826635A4 (en) 2022-04-27
CA3106995A1 (en) 2020-01-30
EP3826635A1 (en) 2021-06-02
CN118512452A (zh) 2024-08-20
US20200022974A1 (en) 2020-01-23
MX2021000908A (es) 2021-06-08
CN112703000B (zh) 2024-05-31
BR122023024228A2 (pt) 2024-02-20
CN118477079A (zh) 2024-08-13
IL280301B1 (en) 2025-02-01
IL280301A (en) 2021-03-01
AU2019309913B2 (en) 2025-02-27
WO2020023486A1 (en) 2020-01-30
US20250339424A1 (en) 2025-11-06
CN118512451A (zh) 2024-08-20
IL280301B2 (en) 2025-06-01
AU2025203754A1 (en) 2025-06-12
MX2024009649A (es) 2024-08-19
CN118512453A (zh) 2024-08-20
US11660296B2 (en) 2023-05-30
BR112021001177A2 (pt) 2021-04-27
KR20210035854A (ko) 2021-04-01
US20240423975A1 (en) 2024-12-26
US20220218697A1 (en) 2022-07-14
US20220409613A1 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
JP7072280B2 (ja) 抗そう痒剤
JP5886632B2 (ja) オキシコドンおよびナロキソンを含む即時放出医薬組成物
US20240423975A1 (en) Treatment of chronic cough, breathlessness and dyspnea
WO2005123074A9 (en) Use of a compound in the treatment of sleep disorders
KR20130106431A (ko) 파킨슨병의 치료에 있어서 오피오이드 효능제와 오피오이드 길항제의 조합물
US20230338367A1 (en) Treatment of prurigo nodularis
JP2026506102A (ja) 疼痛緩和に有用なレジメンおよび組成物
HK40109449A (zh) 慢性咳嗽、呼吸急促和呼吸困难的治疗
HK40109450A (zh) 慢性咳嗽、呼吸急促和呼吸困难的治疗
HK40109451A (zh) 慢性咳嗽、呼吸急促和呼吸困难的治疗
HK40109448A (zh) 慢性咳嗽、呼吸急促和呼吸困难的治疗
HK40045293B (zh) 慢性咳嗽、呼吸急促和呼吸困难的治疗
HK40045293A (en) Treatment of chronic cough, breathlessness and dyspnea
WO2026025110A1 (en) Treatment of refractory chronic cough
WO2026035694A1 (en) Cebranopadol useful for preventing or reducing opioid induced respiratory depression
HK40003409A (en) Treatment of prurigo nodularis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220721

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240402

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20240527

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240806

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240828

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20241129